Timber pharmaceuticals announces late-breaking presentation at the american academy of dermatology 2022 annual meeting

Sub-analysis of the phase 2b control study in congenital ichthyosis demonstrates treatment success with tmb-001 regardless of subtype

TMBR Ratings Summary

TMBR Quant Ranking